Advertisement

Topics

C. R. Bard, Inc. Company Profile

01:36 EST 18th November 2017 | BioPortfolio

Cost of goods sold


News Articles [27 Associated News Articles listed on BioPortfolio]

C.R. Bard Declares Quarterly Dividend

MURRAY HILL, N.J.--(BUSINESS WIRE)--The Board of Directors of C. R. Bard, Inc. (NYSE-BCR) today declared a regular quarterly dividend of 26 cents per share on Bard's common stock. In conne...

Extension of tender offer for Bard notes announced by BD

A tender offer for up to $1.1 billion in outstanding C. R. Bard notes has been extended again by Becton Dickinson from Oct.  -More- 

Merit Medical Coughs Up $100M for Bard, BD's Biopsy Assets

Merit's proposed asset acquisition is subject to the closing of BD’s proposed acquisition of Bard as well as other closing conditions.

$24B Becton Dickinson merger secures C.R. Bard shareholder approval

A merger deal between Becton Dickinson and C.R. Bard, valued at $24 billion, received approval from C.R.  -More- 

Grant from CR Bard Supports Music Therapy at NJ Adult Day Center

Basking Ridge, NJ (PRWEB) July 21, 2017 The Visiting Nurse Association of Somerset Hills (VNA) has received a $5,000 grant from th...

C. R. Bard, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 13062017] Prices from USD $350

C. R. Bard, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's C. R. Bard, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report i...

C.R. Bard's covered iliac stent gets premarket approval from FDA

The FDA has given C.R.  -More- 

Merit Medical - Becton And Bard Deal Looks Nice

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Cordran [Watson Pharma, Inc.]

Cordran® Tape Flurandrenolide Tape, USP For the Physician Rx only Revised: May 2010

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease: A meta-analysis.

Many noninvasive methods for diagnosing liver fibrosis (LF) have been proposed. To determine the best method for diagnosing LF in nonalcoholic fatty liver disease (NAFLD), we conducted a systemic revi...

Size-Controllable Gold Nanopores with High SERS Activity.

Nanopore structures have been successfully employed in next generation DNA sequencing. For more complicated protein which normally contains 20 different amino acids, identifying the fluctuation of ion...

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

Study Of Hernia Repair Utilizing The Bard Ventrio Hernia Patch

This study will collect data on patients undergoing hernia repair using the Bard Ventrio Hernia Patch. The study will evaluate hernia recurrence rates, operating time, quality of life and...

Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System

The medical device being examined in this study is the Bard® LifeStent® 5F Vascular Stent System. It is intended for use in patients who suffer from peripheral artery disease (PAD). PAD ...

A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries

To assess the safety and efficacy of the BARD LTX DCB for treatment of stenosis or occlusion of the superficial femoral and popliteal arteries.

The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ Stent

This study will look at the performance of the Cordis S.M.A.R.T.™ CONTROL ™ Nitinol Stent System for the treatment of TASC C & D superficial femoral artery long lesions (up to 22 cm) i...

BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease

The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment o...

Companies [13 Associated Companies listed on BioPortfolio]

CR Bard

C. R. Bard, Inc. is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialt...

C. R. Bard, Inc

C. R. Bard, Inc. is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialt...

BISNAR | CHASE

The BISNAR | CHASE Orange County, California Bard Avaulta Mesh Lawyers represent people who have been very seriously injured or lost a family member due to defective products such...

C.R. Bard, Inc.

Bard Peripheral Vascular OEM Products

More Information about "C. R. Bard, Inc." on BioPortfolio

We have published hundreds of C. R. Bard, Inc. news stories on BioPortfolio along with dozens of C. R. Bard, Inc. Clinical Trials and PubMed Articles about C. R. Bard, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of C. R. Bard, Inc. Companies in our database. You can also find out about relevant C. R. Bard, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record